Trimodality Therapy COE Articles

Articles

  • A Comparison of Trimodality Therapy to Radical Cystectomy for Muscle Invasive Bladder Cancer - Expert Commentary

    Radical cystectomy and Trimodality therapy, which combines transurethral resection of the bladder tumor (TURBT) and concurrent chemoradiation, are effective treatments for muscle-invasive bladder cancer (MIBC). A recent study investigated the outcomes of patients with MIBC who were eligible for both treatment options.
    Published August 14, 2023
  • ASCO GU 2022: Bladder-Sparing Trimodality Therapy: Toxicity and Functional Outcomes in the Era of Novel Therapeutics

    (UroToday.com) On the second day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022, Dr. Sophia Kamran presented in a session highlighting novel therapies in bladder cancer and their toxicities, discussing the role of bladder-sparing trimodality therapy with a focus on toxicity and functional outcomes.

    Published February 25, 2022
  • ASCO GU 2022: Multi-Institutional Matched Comparison of Radical Cystectomy to Trimodality Therapy for Muscle-Invasive Bladder Cancer

    (UroToday.com) On the second day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022 focusing on urothelial carcinoma, Dr. Zlotta presented a comparison of radical cystectomy and trimodality therapy in the treatment of patients with muscle-invasive bladder cancer (MIBC) in a session focused on a Potpourri of Hot Topics in Urothelial Carcinoma.

    Published February 19, 2022
  • ASTRO 2022: Multi-Institutional Matched Comparison of Radical Cystectomy to Trimodality Therapy for Muscle Invasive Bladder Cancer

    (UroToday.com) The 2022 ASTRO annual meeting featured a session on bladder and kidney preservation, including a presentation by Dr. Jason Efstathiou discussing a multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle invasive bladder cancer. There is a growing body of evidence for trimodality therapy regarding efficacy and safety, and it is now an accepted option by a number of guidelines in selected patients with muscle invasive bladder cancer. However, prior randomized controlled trials comparing bladder preservation to radical cystectomy for muscle invasive bladder cancer closed early due to lack of accrual (ie. the SPARE trial). Given that no future randomized controlled trials are foreseen, and in the absence of level 1 data, Dr. Efstathiou and colleagues aimed to provide the best evidence possible on outcomes of matched cohorts comparing trimodality therapy (maximal transurethral resection of bladder tumor followed by concurrent chemoradiation) to radical cystectomy in order to guide management.

    Published October 26, 2022
  • IBCN 2022: Propensity Matched Comparison of Radical Cystectomy with Trimodality Therapy for Muscle Invasive Bladder Cancer: A Multi-Institutional Study

    (UroToday.com) Prior randomized controlled trials comparing bladder preservation to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) closed due to lack of accrual. None are foreseen in the near future. Thus, we aimed to compare trimodality therapy (TMT, maximal transurethral resection of bladder tumor followed by concurrent chemoradiation) to radical cystectomy (RC) in matched cohorts of patients with MIBC.

    Published September 30, 2022
  • Quality of Life in Trimodality Therapy

    (UroToday.com) In anticipation of the 2021 American Urological Association (AUA) Annual Meeting which is being held, in a delayed fashion, in September, the AUA hosted a “May Kick-Off Weekend” which highlighted a variety of important topics in both benign urology and urologic oncology. Saturday afternoon, Adam Feldman led a course entitled “Trimodality Therapy (TMT) for Management of Muscle Invasive Bladder Cancer” along with faculty Richard Lee and Jason Efstathiou.

    Published May 23, 2021
  • Radical Cystectomy versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Beyond the Abstract

    Radical cystectomy is widely used in muscle-invasive bladder cancer management, but even with improvements in surgical technique, it remains a major operation with significant morbidity, perioperative mortality, and quality of life-altering changes. Bladder preservation has been evaluated as a treatment for muscle-invasive bladder cancer since the 1980s, in hopes of offering better quality of life and to avoid complications due to surgery while maintaining comparable oncological outcomes.
    Published August 10, 2023
  • Rationale and Selection for Trimodality Therapy

    (UroToday.com) In anticipation of the 2021 American Urological Association Annual Meeting which is being held, in a delayed fashion, in September, the AUA hosted a “May Kick-Off Weekend” which highlighted a variety of important topics in both benign urology and urologic oncology. Saturday afternoon, Adam Feldman led a course entitled “Trimodality Therapy for Management of Muscle Invasive Bladder Cancer” along with faculty Richard Lee and Jason Efstathiou.
    Published May 23, 2021
  • Surveillance After Trimodality Therapy

    (UroToday.com) In anticipation of the 2021 American Urological Association (AUA) Annual Meeting which is being held, in a delayed fashion, in September, the AUA hosted a “May Kick-Off Weekend” which highlighted a variety of important topics in both benign urology and urologic oncology. Saturday afternoon, Adam Feldman led a course entitled “Trimodality Therapy (TMT) for Management of Muscle Invasive Bladder Cancer” along with faculty Richard Lee and Jason Efstathiou.

    Published May 23, 2021
  • The Role of Chemotherapy in Trimodality Therapy

    (UroToday.com) In anticipation of the 2021 American Urological Association (AUA) Annual Meeting which is being held, in a delayed fashion, in September, the AUA hosted a “May Kick-Off Weekend” which highlighted a variety of important topics in both benign urology and urologic oncology. Saturday afternoon, Adam Feldman led a course entitled “Trimodality Therapy (TMT) for Management of Muscle Invasive Bladder Cancer” along with faculty Richard Lee and Jason Efstathiou.

    Published May 23, 2021
  • Trimodality Therapy Paradigm and Outcomes

    (UroToday.com) In anticipation of the 2021 American Urological Association (AUA) Annual Meeting which is being held, in a delayed fashion, in September, the AUA hosted a “May Kick-Off Weekend” which highlighted a variety of important topics in both benign urology and urologic oncology. Saturday afternoon, Adam Feldman led a course entitled “Trimodality Therapy (TMT) for Management of Muscle Invasive Bladder Cancer” along with faculty Richard Lee and Jason Efstathiou.
    Published May 23, 2021